Approved Biospecimen Research

View a listing of Washington University investigators (pdf) who are approved to conduct COVID-19 research with biospecimens. This roster will be updated regularly as new studies are approved.

Listen to a recording (WUSTL key required) of the June 2, 2020 meeting with current COVID-19 biospecimen users to discuss research plans and sharing of clinical and experimental data.

Approved protocols for COVID-19 biospecimen collection at Washington University are outlined below.

Name/TitleDescriptionSamples collectedClinical data
WU350 (IRB#202003085)

Immunological, genetics and clinical predictors of SARS CoV-2 infection
ED and inpatient based recruitment, with samples collected at up to 6 time points (0,3,7,14,28,84). Follow-up outpatient in ID clinic
(Goal recruitment=300)
Cryopreserved Cells

Location: Tissue Procurement Core
REDCap and I2 DataCommons
WU353 (IRB# 202003186)

Registry and screening of participants with history of confirmed SARS CoV-2 infection to evaluate for eligibility for donation of convalescent plasma
Donor plasma protocol, single time point (Goal=5/d)Plasma
Cryopreserved Cells

Location: Tissue Procurement Core
REDCap and I2 DataCommons
OB/GYN (IRB# 202003130)

Course of COVID-19 Infection in Pregnancy
Inpatient and outpatient collection from pregnant women and infantsBlood
NP swabs
amniotic fluid

Location: WIHSC
RADx-UP WUIDDRC (IRB# 202009060)

Supporting the health and well-being of children during the COVID-19 pandemic
Weekly samples from participantsSaliva

Location: IDDRC
Not applicable

IRB# 202006151

Linking inflammatory phenotypes and biomarkers to trajectories and outcomes in patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS)
Mechanically ventilated

patients with paired BAL and plasma samples collected
BAL, serumNot applicable


Process for Obtaining Biospecimens

View an overview of the process for obtaining biospecimens for COVID-19 research at Washington University (pdf).